Drug intelligence / Profile preview

ALP-2102

Development stage: Unknown
Lead developer: Asieris Pharmaceuticals
Administration: Oral

Overview

ALP-2102 is an oral drug developed by Asieris Pharmaceuticals. It is currently being investigated as a neoadjuvant therapy for patients with muscle invasive bladder cancer. This drug is being evaluated in combination with BeiGene's tislelizumab. Asieris plans to submit an Investigational New Drug (IND) application in China to conduct a Phase I/II study to assess its safety and determine the recommended Phase II dose. The specific mechanism of action and modality of ALP-2102 are not publicly disclosed in the available information.

Beyond the preview

Go deeper on ALP-2102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALP-2102.

Explore the full profile